RxDoctor Payments Data

Kevin Holmes, MD

Internal Medicine · Columbia, MSNPI 1942297858

Payments from drug & device makers

$2,743in general payments, 2019–2025

Across 148 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$720
  • AstraZeneca$233
  • Astellas Pharma US Inc$198
  • AbbVie$185
  • Pfizer$176
  • Johnson & Johnson$122
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$2,66397%
  • Education$803%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,743 in reported general payments places this provider in the 80th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$241,785
Medicare patients
444
Services billed
3,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide222$300,735
JardianceEmpagliflozin176$201,261
EliquisApixaban145$147,819
LinzessLinaclotide134$119,038
MounjaroTirzepatide81$116,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter116$96,588
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog53$76,147
Thiola EcTiopronin14$74,215
JanuviaSitagliptin Phosphate63$64,356
XareltoRivaroxaban84$59,463
KerendiaFinerenone61$50,235
TrulicityDulaglutide29$46,359
MyrbetriqMirabegron76$42,315
FarxigaDapagliflozin Propanediol60$41,550
RybelsusSemaglutide25$35,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$94$336,488247 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Trijardy Xr$80$253,522249 claims
Lilly USA, LLCMounjaro, Trulicity$77$162,377110 claims
AbbVieLinzess, Vraylar, Qulipta$185$158,642166 claims
PfizerEliquis$176$147,819145 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$233$73,241107 claims
Johnson & JohnsonXarelto$122$59,46384 claims
BayerKerendia$70$50,23561 claims
Astellas Pharma US IncMyrbetriq$198$42,31576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Columbia

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →